22 May 2013
Keywords: GW Pharmaceuticals, Type 2 diabetes, Cannabinoids, Metabolic syndrome
Article | 01 October 2010
UK-based GW Pharmaceuticals (GWP: AIM) has commenced the first of a program of Phase IIa exploratory clinical trials exploring its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 October 2010
30 September 2010
© 2013 thepharmaletter.com